GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (TSXV:MRVL) » Definitions » Earnings per Share (Diluted)

Marvel Biosciences (TSXV:MRVL) Earnings per Share (Diluted) : C$-0.04 (TTM As of Oct. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Marvel Biosciences Earnings per Share (Diluted)?

Marvel Biosciences's Earnings per Share (Diluted) for the three months ended in Oct. 2024 was C$-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2024 was C$-0.04.

Marvel Biosciences's EPS (Basic) for the three months ended in Oct. 2024 was C$-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Oct. 2024 was C$-0.04.

Marvel Biosciences's EPS without NRI for the three months ended in Oct. 2024 was C$-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Oct. 2024 was C$-0.04.

During the past 3 years, the average EPS without NRIGrowth Rate was 13.60% per year.

During the past 5 years, Marvel Biosciences's highest 3-Year average EPS without NRI Growth Rate was 13.60% per year. The lowest was -27.40% per year. And the median was -6.90% per year.


Marvel Biosciences Earnings per Share (Diluted) Historical Data

The historical data trend for Marvel Biosciences's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Earnings per Share (Diluted) Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24
Earnings per Share (Diluted)
-0.03 -0.17 -0.08 -0.06 -0.04

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Competitive Comparison of Marvel Biosciences's Earnings per Share (Diluted)

For the Biotechnology subindustry, Marvel Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marvel Biosciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's PE Ratio falls into.



Marvel Biosciences Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Marvel Biosciences's Earnings Per Share (Diluted) for the fiscal year that ended in Jul. 2024 is calculated as

Diluted Earnings Per Share (A: Jul. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.65-0)/39.964
=-0.04

Marvel Biosciences's Earnings Per Share (Diluted) for the quarter that ended in Oct. 2024 is calculated as

Diluted Earnings Per Share (Q: Oct. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.278-0)/44.786
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Marvel Biosciences  (TSXV:MRVL) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Marvel Biosciences Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Marvel Biosciences Business Description

Traded in Other Exchanges
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.
Executives
Joseph Roderick Matheson Director, Senior Officer
Neil Allan Johnson Director
Jacqueline Groot Senior Officer